Clinical reference Biomarker Directory
Back to directory

Interleukin-10

Emerging

CSF IL-10, especially the IL-10:IL-6 ratio, is a supportive marker helping diagnose primary CNS lymphoma before biopsy.

Also known as IL-10 interleukin-10
In plain language

IL-10 usually calms down inflammation, but in spinal fluid, unusually high levels are actually a clue pointing toward a specific type of brain lymphoma, helping doctors distinguish it from other possible causes of a brain lesion before doing a biopsy.

Biomarker & context

Interleukin-10 (IL-10) is an anti-inflammatory cytokine that, somewhat counterintuitively, is often elevated in certain aggressive disease states rather than only in states of immune suppression.

What it indicates

Markedly high cerebrospinal fluid (CSF) IL-10, especially an elevated IL-10:IL-6 ratio, is a well-established supportive marker for primary CNS lymphoma, helping distinguish it from other CNS lesions (like inflammatory demyelinating disease or other tumors) before biopsy confirmation.

Diagnosis & clinical testing

Measured via CSF immunoassay in the specific context of suspected primary CNS lymphoma workup, alongside imaging and eventual tissue biopsy for definitive diagnosis; it's a supportive, not standalone diagnostic, test.

Guiding treatment

An elevated CSF IL-10:IL-6 ratio supports proceeding with a diagnostic biopsy for suspected primary CNS lymphoma with greater confidence, though biopsy remains the definitive diagnostic step in essentially all cases.

Clinical significance

An example of an anti-inflammatory cytokine paradoxically serving as a marker of aggressive malignant disease.

References
  1. General neuro-oncology reference literature on CSF IL-10 and the IL-10:IL-6 ratio in primary CNS lymphoma diagnosis.